Merrimack Sells Pancreatic Cancer Drug to Ipsen for $1 Billion
Merrimack Pharmaceuticals agreed to sell oncology treatments, including its pancreatic-cancer treatment Onivyde, to French drugmaker Ipsen.
Merrimack Pharmaceuticals' (MACK) - Get Report shares soared 43% in pre-market trading to $5.16 as news broke the company sold its pancreatic-cancer treatment Onivyde to French drugmaker Ipsen (IPSEY) .
This article was written by a staff member of TheStreet.
